Drugs / huCART19-IL18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04684563 | May 2021 → May 2036 expected | B-cell chronic lymphocytic leukemia | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huCART19-IL18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04684563 ↗ |
| Modality | Cell therapy | “autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)” NCT04684563 ↗ |
| Route | Intravenous | “administered as a single intravenous (IV) infusion or slow IV push” NCT04684563 ↗ |
| Target | CD19 | “autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen” NCT04684563 ↗ |